Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ROZEREM
Published 2026-03-24 · Last reviewed 2026-03-31 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Ramelteon is a melatonin receptor agonist (MT1/MT2) approved for insomnia and is generally used for sleep onset symptoms.
Ramelteon is typically a better fit for sleep-onset complaints than for frequent nighttime awakenings; if sleep maintenance is the primary issue, consider alternative strategies rather than dose escalation.
It is not a controlled substance and is often considered when misuse or dependence risk makes sedative-hypnotics less desirable.
Effect size is often modest; set expectations, pair with CBT-I and sleep hygiene, and reassess benefit within a few weeks rather than escalating to hypnotic polypharmacy.
The ramelteon compare view, ramelteon evidence feed, and ramelteon print page can support building a sleep plan that prioritizes safety and avoids stacking sedatives.
Effect size is often modest; pair with CBT-I and sleep hygiene and reassess benefit rather than escalating to polypharmacy. Ramelteon is not a controlled substance and has low misuse potential, which can be valuable when substance use risk makes sedative-hypnotics undesirable; still use a clear reassessment checkpoint and discontinue if there is no meaningful benefit.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Agonist at melatonin MT1 and MT2 receptors, supporting sleep onset by modulating circadian signaling.
Does not act on GABA-A receptors and is not a benzodiazepine-class sedative-hypnotic.
Because it is not GABAergic, ramelteon does not provide rapid “knockout” sedation; it works best when circadian misalignment and sleep-onset difficulty are key drivers.
Sources: FDA/DailyMed label; AASM insomnia guideline; evidence reviews.